A member-only episode looks at peptides, which fans tout for healing and muscle gain, and asks whether those claims hold up.
Recap by typeshit. Post by Facebook on Facebook.
Pratt, a psychology professor who studies the circuits behind food motivation, walks through what neuroscience shows about these drugs.
Lilly's pill had major heart events in 4.2% of patients vs 5.0% on insulin glargine. The Clinical Trial Vanguard argues rivals now need to show benefit, not just safety.
A Future Health & Medical Innovation panel weighs how much of the growing interest in peptides and exosomes is backed by evidence.
The aging doctor shares a headline saying new studies point to GLP-1 drugs slowing the biological clock, and notes himself that more research is needed.
A short wellness post arguing that the scale misses part of the picture for people on semaglutide or tirzepatide. Light on specifics.
Mounting research suggests GLP-1 medications used for diabetes and weight loss may also dampen people's desire for drugs and alcohol.
Loading…